These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10204634)

  • 1. Pharmacological considerations in the emergence of resistance.
    Amsden GW
    Int J Antimicrob Agents; 1999 Mar; 11 Suppl 1():S7-14; discussion S31-2. PubMed ID: 10204634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae.
    Lacy MK; Owens RC; Xu X; Nicolau DP; Quintiliani R; Nightingale CH
    Int J Antimicrob Agents; 1998 Nov; 10(4):279-83. PubMed ID: 9916901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae.
    Stein GE; Schooley S
    Diagn Microbiol Infect Dis; 2001 Mar; 39(3):181-5. PubMed ID: 11337186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
    Carbon C; Poole MD
    J Chemother; 1999 Apr; 11(2):107-18. PubMed ID: 10326741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015.
    Jakubů V; Zavadilová J; Fabiánová K; Urbášková P
    Cent Eur J Public Health; 2017 Dec; 25(4):282-286. PubMed ID: 29346850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance.
    Burgess DS; Hastings RW; Horan JL
    Ann Pharmacother; 1999 Dec; 33(12):1262-5. PubMed ID: 10630825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The macrolides: erythromycin, clarithromycin, and azithromycin.
    Alvarez-Elcoro S; Enzler MJ
    Mayo Clin Proc; 1999 Jun; 74(6):613-34. PubMed ID: 10377939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of macrolides against intracellular Legionella pneumophila.
    Segreti J; Meyer P; Kapell K
    Diagn Microbiol Infect Dis; 1996 Jul; 25(3):123-6. PubMed ID: 8902407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus.
    Maurer FP; Castelberg C; Quiblier C; Böttger EC; Somoskövi A
    J Antimicrob Chemother; 2014 Jun; 69(6):1559-63. PubMed ID: 24500188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
    Kays MB; Denys GA
    Clin Ther; 2001 Mar; 23(3):413-24. PubMed ID: 11318076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin.
    Yeates RA; Laufen H; Zimmermann T; Schumacher T
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):577-9. PubMed ID: 9455717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions.
    Wildfeuer A; Laufen H; Zimmermann T
    Antimicrob Agents Chemother; 1996 Jan; 40(1):75-9. PubMed ID: 8787883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes.
    De Vecchi E; Nicola L; Zucchetti E; Drago L
    J Chemother; 2006 Aug; 18(4):379-88. PubMed ID: 17024793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro comparative dynamics of modified-release clarithromycin and of azithromycin.
    Scaglione F; Demartini G; Dugnani S; Fraschini F
    Chemotherapy; 2000; 46(5):342-52. PubMed ID: 10965100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary disposition of erythromycin, azithromycin, and clarithromycin in foals.
    Suarez-Mier G; Giguère S; Lee EA
    J Vet Pharmacol Ther; 2007 Apr; 30(2):109-15. PubMed ID: 17348895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Azithromycin: critical points].
    Philippon A; Cluzel R; Soussy CJ
    Pathol Biol (Paris); 1995 Jun; 43(6):488-97. PubMed ID: 8539070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin.
    Nilsen OG
    Infection; 1995; 23 Suppl 1():S5-9. PubMed ID: 7782117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced-generation macrolides: tissue-directed antibiotics.
    Amsden GW
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S11-5. PubMed ID: 11574189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The newer macrolides. Azithromycin and clarithromycin.
    Zuckerman JM; Kaye KM
    Infect Dis Clin North Am; 1995 Sep; 9(3):731-45. PubMed ID: 7490441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythromycin, clarithromycin, and azithromycin: are the differences real?
    Amsden GW
    Clin Ther; 1996; 18(1):56-72; discussion 55. PubMed ID: 8851453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.